Literature DB >> 12576089

Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin.

A Mollet1, S Meier, V Grabler, S Gilg, E Scharrer, T A Lutz.   

Abstract

Previous studies indicated that amylin contributes to the anorectic effects of cholecystokinin (CCK) and bombesin (BBS), possibly by enhancing the release of pancreatic amylin or by modulating their anorectic actions within the central nervous system (CNS). To elucidate the interaction between amylin and CCK or BBS, respectively, we investigated the influence of an IP injection of CCK or BBS on feeding in amylin-deficient mice (IAPP(-/-)). The anorectic effects of CCK and BBS were nearly abolished in IAPP(-/-) mice compared to wildtype (WT) mice (e.g. 20 microg/kg CCK, 1-h food intake: WT/NaCl 0.53 +/- 0.03 g; WT/CCK 0.16 +/- 0.03 g (P < 0.001); IAPP(-/-)/NaCl 0.49 +/- 0.05 g; IAPP(-/-)/CCK 0.39 +/- 0.04 g). Acute amylin replacement restored the anorectic effect of CCK in IAPP(-/-) mice. To find out whether CCK or BBS enhance the feeding-induced release of pancreatic amylin, we injected rats with CCK-8 (0.5-50 microg/kg) or BBS (5 microg/kg) and measured plasma amylin levels after injections. Neither CCK nor BBS increased the plasma amylin level in rats. We suggest that the mediation of the anorectic effects of CCK and BBS by amylin is not dependent on a CCK- or BBS-induced release of pancreatic amylin, but may rather be due to a modulation of their effects by amylin within the CNS. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576089     DOI: 10.1016/s0196-9781(02)00280-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

Review 1.  Central control of body weight and appetite.

Authors:  Stephen C Woods; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

Review 2.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake.

Authors:  Elizabeth G Mietlicki-Baase; Diana R Olivos; Brianne A Jeffrey; Matthew R Hayes
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-04-21       Impact factor: 4.310

Review 4.  Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.

Authors:  Laurence J Miller; Aditya J Desai
Journal:  Trends Endocrinol Metab       Date:  2016-05-04       Impact factor: 12.015

Review 5.  Control of energy homeostasis by amylin.

Authors:  Thomas A Lutz
Journal:  Cell Mol Life Sci       Date:  2011-12-23       Impact factor: 9.261

Review 6.  Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.

Authors:  T A Lutz
Journal:  Int J Obes Suppl       Date:  2016-11-16

Review 7.  Integration of satiety signals by the central nervous system.

Authors:  Adam P Chambers; Darleen A Sandoval; Randy J Seeley
Journal:  Curr Biol       Date:  2013-05-06       Impact factor: 10.834

8.  Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity.

Authors:  Ambrose A Dunn-Meynell; Christelle Le Foll; Miranda D Johnson; Thomas A Lutz; Matthew R Hayes; Barry E Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-12-16       Impact factor: 3.619

Review 9.  Amylin at the interface between metabolic and neurodegenerative disorders.

Authors:  Thomas A Lutz; Urs Meyer
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

Review 10.  Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat.

Authors:  David S Mathiesen; Asger Lund; Tina Vilsbøll; Filip K Knop; Jonatan I Bagger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-08       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.